SAN DIEGO – (COMMERCIAL THREAD) – BioDuro-Sundia, a leading drug discovery and development services organization backed by Advent International, today announced that it has entered into a definitive agreement to acquire a fully operational 45,000-foot site2 Commercial oral solid dose pharmaceutical manufacturing facility located at 9601 Jeronimo Road, Irvine, CA. As part of the acquisition, BioDuro-Sundia will employ most of the current staff and provide ongoing operations to support production of several existing products through a commercial supply agreement. Subject to the usual closing conditions, BioDuro-Sundia will enter into activity on January 1, 2022.
Jeronimo’s facility is located in Irvine, Calif., On the same campus as BioDuro-Sundia’s first US-based commercial facility, announced in August 2021. The agreement includes an additional 25,000 feet2 future space with combined facilities representing ~ 100,000 feet2 with a supply capacity> 4 billion doses per year. Commercial production capabilities include an aqueous and organic solvent process for fluidized bed and coating capabilities, amorphous solid dispersion, as well as several high speed compression and encapsulation machines.
âBusiness continuity, including a highly experienced team and established processes, allows for a seamless transition to commercial manufacturing in a facility with an exceptional production and audit history,â said Alex Rodriguez, Director general of Irvine’s installation at BioDuro-Sundia. “But, we are also adding new capabilities on a commercial scale, such as dry spray dispersion and hot extrusion, which make us one of the leading suppliers of amorphous solid dispersions manufacturing in North America. ”
âThe acquisition of these commercial drug production facilities is a milestone in our 25 year history, pioneering the improvement of bioavailability for oral solid dosage forms, and a credit to our team’s dedication to drug operations. quality, customer satisfaction and growth, âsaid Kent Payne, who led the acquisition in his role as President, US / EU Development and Manufacturing at BioDuro-Sundia. âIt is also representative of our commitment to the company’s customers and the investments we continue to make to increase capacity, establish new technologies and help our partners succeed. We look forward to supporting our commercial phase customers with the manufacture of quality pharmaceutical products, as do all of our customers who entrust us with critical programs, from discovery to development to manufacturing. ”
BioDuro-Sundia’s clinical development facility in the United States is located just an hour’s drive south of San Diego, California. The development operation has a track record of over 1,000 clinical programs specializing in improving solubility by taking advantage of amorphous solid dispersions.
BioDuro-Sundia, a portfolio company of Advent International, is a leading contract research, development and manufacturing (CRDMO) organization that provides biopharmaceutical partners with fully integrated services to support discovery, development and manufacture of medicaments for the drug substance and drug product. The company is the third largest in the industry, with major operations in China and the United States, with more than 2,000 employees and 10 locations worldwide.
Core expertise includes discovery, development and scaling of small and large molecules, support for IND submission, and unique technology platforms such as improving the bioavailability of insoluble compounds. The company has research sites, as well as GMP manufacturing facilities in China and the United States. The one-stop-shop operation helps biopharmaceutical partners around the world dramatically accelerate risk reduction discovery and development to create higher value-added outcomes.
BioDuro-Sundia’s investment is led by Advent International, with support from Bridgewest Business Group.
For more information visit: www.bioduro-sundia.com
About Avent International
Founded in 1984, Advent International is one of the world’s largest and most experienced private equity investors. The company has invested in more than 350 private equity deals in 41 countries and, as of June 30, 2020, had $ 58.4 billion in assets under management. With 15 offices in 12 countries, Advent has established a globally integrated team of more than 200 investment professionals in North America, Europe, Latin America and Asia. The company focuses on investments in five key sectors, including business and financial services; health care; industrial; retail, consumer and leisure; and technology. After 35 years of international investing, Advent remains committed to partnering with management teams to generate sustained revenue and earnings growth for its portfolio companies.
For more information visit: www.adventinternational.com
About Bridgewest Business Group
Founded in 1999, The Bridgewest Business Group is a private equity investment firm that seeks to create long-term value by applying superior industry knowledge, operational expertise and significant financial resources to business opportunities. attractive investment. The Group structures its global investments in four functional areas, including private equity, real estate, capital markets and financial services. The Group’s private equity investments are mainly in biotechnology, wireless communications, IoT infrastructure and semiconductors. Bridgewest is based in San Diego, California, and has investments in the United States, Europe, Asia, and Australasia.
For more information visit: www.bridgewestgroup.com